Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Just In
Mortgage rate relief: Average rate on a 30-year mortgage holds steady at 6.35%, its lowest level since May of 2023
Program
Thursday at 6 on WRAL: ð¦ Hazardous packages on your doorstep. How 1 billion packages from China bypassed safety inspectionsâand why itâs legal.
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Astri Therapeutics Inc
(NQ:
ATXS
)
11.37
-0.13 (-1.13%)
Streaming Delayed Price
Updated: 1:09 PM EDT, Sep 5, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
80,967
Open
11.47
Bid (Size)
11.37 (4)
Ask (Size)
11.40 (1)
Prev. Close
11.50
Today's Range
11.28 - 11.55
52wk Range
4.260 - 16.90
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 04, 2024
From
Astria Therapeutics
Via
Business Wire
Astria Therapeutics to Present at Upcoming Bradykinin Symposium
August 30, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Performance
YTD
+45.96%
+45.96%
1 Month
+14.96%
+14.96%
3 Month
+23.86%
+23.86%
6 Month
-22.65%
-22.65%
1 Year
+29.06%
+29.06%
More News
Read More
Astria Therapeutics to Participate in Upcoming Morgan Stanley 22nd Annual Global Healthcare Conference
August 29, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
ATXS Stock Earnings: Astria Therapeutics Misses EPS for Q2 2024
August 12, 2024
Via
InvestorPlace
Astria Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
August 12, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Chooses Ypsomed’s YpsoMate as the Injection Device for STAR-0215 for the Treatment of Hereditary Angioedema
August 12, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Participate in Upcoming 2024 Wedbush PacGrow Healthcare Conference
August 07, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2024
From
Astria Therapeutics
Via
Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 04, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference
May 30, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference
May 24, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress
May 23, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
ATXS Stock Earnings: Astria Therapeutics Misses EPS for Q1 2024
May 09, 2024
Via
InvestorPlace
Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
May 09, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present at Upcoming Society for Investigative Dermatology Annual Meeting
May 08, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors
April 09, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE
March 25, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Why Lifecore Biomedical Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
March 20, 2024
Via
Benzinga
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 05, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
ATXS Stock Earnings: Astria Therapeutics Misses EPS for Q4 2023
March 04, 2024
Via
InvestorPlace
Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
March 04, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting
February 20, 2024
From
Astria Therapeutics, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.